ZIOPHARM Oncology (NASDAQ:ZIOP) was upgraded by Zacks Investment Research from a “sell” rating to a “hold” rating in a research note issued on Friday.
According to Zacks, “ZIOPHARM Oncology, Inc. is a biopharmaceutical company engaged in the development and commercialization of a diverse, risk-sensitive portfolio of in-licensed cancer drugs to address unmet medical needs. The Company applies new insights from molecular and cancer biology to understand the efficacy and safety limitations of approved and developmental cancer therapies and identifies proprietary and related molecules for better patient treatment. “
Several other equities analysts have also commented on ZIOP. BidaskClub upgraded shares of ZIOPHARM Oncology from a “strong sell” rating to a “sell” rating in a research report on Thursday, January 4th. HC Wainwright set a $10.00 price objective on shares of ZIOPHARM Oncology and gave the company a “buy” rating in a research report on Thursday, December 14th. Raymond James Financial reiterated a “hold” rating on shares of ZIOPHARM Oncology in a research report on Monday, December 11th. Finally, ValuEngine lowered shares of ZIOPHARM Oncology from a “sell” rating to a “strong sell” rating in a research report on Sunday, December 31st. Two equities research analysts have rated the stock with a sell rating, two have assigned a hold rating and one has given a buy rating to the company’s stock. ZIOPHARM Oncology presently has a consensus rating of “Hold” and a consensus price target of $7.50.
ZIOPHARM Oncology (NASDAQ:ZIOP) last issued its earnings results on Thursday, March 1st. The biotechnology company reported ($0.13) earnings per share for the quarter, hitting the Zacks’ consensus estimate of ($0.13). The company had revenue of $1.60 million for the quarter, compared to the consensus estimate of $1.59 million. During the same quarter in the prior year, the company posted ($0.11) EPS. ZIOPHARM Oncology’s revenue was up .0% compared to the same quarter last year. equities analysts forecast that ZIOPHARM Oncology will post -0.58 earnings per share for the current fiscal year.
A number of hedge funds have recently added to or reduced their stakes in ZIOP. Chevy Chase Trust Holdings Inc. bought a new position in ZIOPHARM Oncology during the third quarter valued at $104,000. G&S Capital LLC bought a new position in ZIOPHARM Oncology during the fourth quarter valued at $125,000. Metropolitan Life Insurance Co. NY bought a new position in ZIOPHARM Oncology during the fourth quarter valued at $139,000. Adell Harriman & Carpenter Inc. bought a new position in ZIOPHARM Oncology during the third quarter valued at $141,000. Finally, Steward Partners Investment Advisory LLC bought a new position in ZIOPHARM Oncology during the third quarter valued at $145,000. Institutional investors and hedge funds own 39.74% of the company’s stock.
ZIOPHARM Oncology Company Profile
ZIOPHARM Oncology, Inc is a biopharmaceutical company, which is seeking to develop, acquire and commercialize, on its own or with partners, a portfolio of cancer therapies that address unmet medical needs. The Company is focused on developing products in immuno-oncology that employ gene expression, control and cell technologies to deliver cell- and viral-based therapies for the treatment of cancer and graft-versus-host-disease.
For more information about research offerings from Zacks Investment Research, visit Zacks.com
Receive News & Ratings for ZIOPHARM Oncology Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for ZIOPHARM Oncology and related companies with MarketBeat.com's FREE daily email newsletter.